FORMULATION : EMERGING MARKETS
More Reyra operates across approximately 70 countries globally, with a strong emphasis on the USA, Asia, and Africa. Additionally, we have a joint venture in Japan.
More Reyra employs a strategic go-to-market approach, leveraging partnerships and a distributor model tailored to diverse market dynamics. This enables us to effectively deliver our specialized product portfolio on a global scale.
More Reyra specializes in manufacturing and supplying a range of immunosuppressant finished products to global markets. Supported by a robust product development and regulatory team, we are committed to assisting our partners in navigating diverse regulatory landscapes worldwide. Emphasizing cGMP compliance, our facilities undergo rigorous inspections by USFDA and other global regulatory authorities. More Reyra is dedicated to delivering high-quality finished products at competitive prices to fulfill the needs of patients globally.
With a strong pipeline of products, More Reyra aims to expand further in global markets through enhanced market penetration and a carefully calibrated strategy
| Sr. No | Brand Name | Generic Name | Dosage | Strength |
|---|---|---|---|---|
| 1 | Mofecon C | Mycophenolate Mofetil | Capsules | 250mg |
| 2 | Mofecon 500 | Mycophenolate Mofetil | Tablets | 500mg |
| 3 | Mofecon OS | Mycophenolate Mofetil | Suspension | 1g/ml |
| 4 | Mofecon S 180 | Mycophenolate Sodium | Tablets | 180mg |
| 5 | Mofecon S 360 | Mycophenolate Sodium | Tablets | 360mg |
| 6 | Tacrolimus 0.5 | Tacrolimus | Capsules | 0.5mg |
| 7 | Tacrolimus 1 | Tacrolimus | Capsules | 1mg |
| 8 | Tacrolimus 5 | Tacrolimus | Capsules | 5mg |